Once again, we could state that GLP-1 RAs are able to offer an additional layer of protection for T2DM patients even under acute stressors like COVID-19, and this is in line with some of the aforementioned studies and meta-analyses [37,40,41,42]: in our cohort of patients the effects of GLP-1 RAs are evident in each step of the analyses performed, and it is linked to significantly lower percentage of death, even after a period of observation of two years. The gene discussed is GLP1R; the disease is COVID-19.